Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher

Syndax Pharmaceuticals Inc

Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.
Botwood most recently SVP, Head of Worldwide Medical Oncology at BMS; brings 25+ years oncology development experience.
Employment terms: base salary $540K, annual target bonus 45%, stock option for 215K shares, PRSU of 23,400 units.
Gallagher will remain for interim transition period; thanked for contributions including two product approvals.
Annual meeting results: all director nominees elected, say-on-pay approved (62.5M for), auditor ratified.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicholas A.J. Botwood

Head of Research and Development, Chief Medical Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2025-05-12
Filed: May 16, 2025, 7:59 PM ET

Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.

Departed

Neil Gallagher

President, Head of Research and Development

SNDX · Syndax Pharmaceuticals Inc

Successor: Nicholas A.J. Botwood
Filed: May 16, 2025, 7:59 PM ET

Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicholas A.J. Botwood was appointed as Head of Research and Development, Chief Medical Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Head of Research and Development, Chief Medical Officer

Exact text from the filing

Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Gallagher resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

Action: resigned
Role: President, Head of Research and Development

Exact text from the filing

Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-25-073555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.